- Home
- LRMR vs NVX Comparison
LRMR vs NVX Comparison
Compare LRMR & NVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LRMR
- NVX
- Stock Information
- Founded
- LRMR N/A
- NVX 2012
- Country
- LRMR United States
- NVX Australia
- Employees
- LRMR N/A
- NVX N/A
- Industry
- LRMR Biotechnology: Pharmaceutical Preparations
- NVX Industrial Machinery/Components
- Sector
- LRMR Health Care
- NVX Miscellaneous
- Exchange
- LRMR Nasdaq
- NVX Nasdaq
- Market Cap
- LRMR 183.8M
- NVX 169.3M
- IPO Year
- LRMR N/A
- NVX N/A
- Fundamental
- Price
- LRMR $2.14
- NVX $1.11
- Analyst Decision
- LRMR Strong Buy
- NVX
- Analyst Count
- LRMR 8
- NVX 0
- Target Price
- LRMR $19.63
- NVX N/A
- AVG Volume (30 Days)
- LRMR 1.3M
- NVX 95.0K
- Earning Date
- LRMR 04-30-2025
- NVX 01-01-0001
- Dividend Yield
- LRMR N/A
- NVX N/A
- EPS Growth
- LRMR N/A
- NVX N/A
- EPS
- LRMR N/A
- NVX N/A
- Revenue
- LRMR N/A
- NVX $5,854,424.00
- Revenue This Year
- LRMR N/A
- NVX $66.66
- Revenue Next Year
- LRMR N/A
- NVX $2,366.64
- P/E Ratio
- LRMR N/A
- NVX N/A
- Revenue Growth
- LRMR N/A
- NVX N/A
- 52 Week Low
- LRMR $1.61
- NVX $0.81
- 52 Week High
- LRMR $11.20
- NVX $2.73
- Technical
- Relative Strength Index (RSI)
- LRMR 54.85
- NVX 40.24
- Support Level
- LRMR $1.80
- NVX $1.15
- Resistance Level
- LRMR $2.33
- NVX $1.42
- Average True Range (ATR)
- LRMR 0.18
- NVX 0.09
- MACD
- LRMR 0.04
- NVX -0.03
- Stochastic Oscillator
- LRMR 90.00
- NVX 1.19
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.
About NVX NOVONIX Limited American Depository Shares
NOVONIX Ltd operates in the lithium-ion battery industry. The company has three operating segments namely Graphite Exploration, Battery Technology, and Battery Materials. Graphite Exploration segment is engaged in the exploration and development of high-grade flake graphite deposits. The Battery Technology segment develops battery cell testing equipment and carries out research and development in battery development. The Battery Materials segment develops and manufactures battery anode materials. The Battery Technology segment generates maximum revenue for the company.